Key facts
- Tachmed’s last known valuation is $24.1M (Mar 2024).
- It has raised $14.6M; the latest was Later Stage VC ($10.0M) in May 2025.
- Notable investors include Balder Capital, Jonathan Fisher, Lady Beaverbrook, Ross Hyatt.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Tachmed
- ·The full record, as it builds
Funding rounds
No funding rounds for Tachmed are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Tachmed
Developer of a primary health diagnostics platform designed for frontline response to a range of health issues, including testing for COVID. The company's platform bridges the last mile of critical remote health services by connecting innovative devices via mobile and web application to an online platform, providing patients with universal access to fast and non-invasive primary health testing.
- Sector
- Healthcare
- HQ
- McLean, VA, United States
- Founded
- 2018
- Employees
- 14
- Website
- tachmed.com/
- Ownership
- Privately Held (backing)
Tachmed doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Tachmed shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Tachmed in its N-PORT filings yet. We sweep new filings monthly.